BIOSPAIN | Regulatory Insights for ATMP development

This session will center around regulatory insights to accelerate the development of ATMPs with a focus on recent experiences coming from Spanish biotech companies and regulatory experts.

This session will center around regulatory insights to accelerate the development of ATMPs with a focus on recent experiences coming from Spanish biotech companies and regulatory experts.
September 20, 2023

ASPHALION expert Chris Mann will be moderating a panel about “Regulatory Insights for #ATMP Development” at BIOSPAIN 2023.

Advanced therapies are medicines for human use that are based on genes, tissues or cells. They offer cutting-edge opportunities for the treatment of disease and injury. They include a complex and innovative class of biopharmaceuticals that are highly research-driven, characterised by innovative manufacturing processes and heterogeneous with regard to their origin, type and complexity. Moreover, these therapies often developed SMEs university and academia with limited regulatory experience.

ATMPS include Medicinal products based on cells or genes which are very different from medicines based on chemical entities or biological / biotechnological origin but are still subject to the same requirements of safety and efficacy. Attrition rates in the regulatory process are disappointingly high.

In this session we will count with:

  • Asphalion, a leading Spanish scientific and regulatory consultancy services firm with extensive experience in the regulatory process of ATMP and member of ARDAT consortium.
  • AEMPS representative who will explain how the Committee for Advanced Therapies supports academic research groups and pharmaceutical companies to foster the development of safe and effective ATMPs.
  • Hospital Clinic researcher with experience in the development of ATMPs and access to the clinics.
  • Splice Bio, who has a proprietary Protein Splicing platform that is applying to develop the next generation of gene therapies.
  • Spark therapeutics, an international biotech company leader in the development of gene therapy.

 

Moderator:

  • Christopher Mann, Scientific & Regulatory Associate Director at Asphalion (Spain)

Speakers:

  • Sol Ruiz, Head of division for Biological Products. Advanced Therapies and Biotechnology AEMPS/EMA (Spain)
  • Manel Juan Otero, Head of inmunology Department at Hospital Clinic (Spain)
  • Miquel Vila-Perelló, PhD, CEO, Splice Bio
  • Yemisi Corinaldi, Regulatory Affairs Leader at Spark Therapeutics (UK)

 

Contact us for further information or queries: info@asphalion.com

 

Event Info

a

Search News & Events

  • Filter by category

Share

Related news and events

EVENT | Symposium AEFI 2024

¡Mañana arranca el 42º Symposium de AEFI! No olvidéis visitarnos en la mesa 6 para conocer de todos los servicios que ofrecemos. Os recordamos los

EVENT | RAPS Euroconvergence

Dates: May 6-8 | Berlin Congress Centre Day 1 at RAPS! ASPHALION’s team is in Berlin!! Come by booth B2 to get to know us

EVENT | 5th IDIBELL Accelerator Meeting Point

The Bellvitge Biomedical Research Institute (IDIBELL) is a biomedical research center created in 2004. It is participated by the Bellvitge University Hospital and the Viladecans Hospital of the Catalan Institute of Health, the Catalan Institute of Oncology, the University of Barcelona and the City Council of L’Hospitalet de Llobregat.

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting